Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC). Isavuconazole (ISAV) is an extended spectrum mold-active triazole and has superior tolerability and fewer significant drug–drug interactions compared with other triazoles.

中文翻译：

---

Isavuconazole作为急性髓细胞性白血病或骨髓增生异常综合症患者的主要抗真菌药物预防：一项开放性，前瞻性，2期研究

对于新诊断为急性髓细胞性白血病（AML）或高危骨髓增生异常综合征（MDS）且正在接受缓解诱导化疗（RIC）的中性粒细胞减少的患者，常规建议使用防霉菌活性抗真菌药物（PAP）。Isavuconazole（ISAV）是一种广谱的霉菌活性三唑，与其他三唑相比，具有更高的耐受性和更少的显着药物相互作用。